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Abstract
 
B7H1 (PDL1) and B7DC (PDL2) are two new members of the B7 family that can interact
with PD-1, a putative negative regulator for immune function. Recent studies have provided
evidence for inhibitory functions of both members via PD-1. Meanwhile, compelling evidence
exists for costimulatory function of both members. Here we demonstrate that expression of
B7DC on the tumor cells promotes CD8 T cell–mediated rejection of tumor cells, at both the
induction and effector phase of antitumor immunity. Moreover, B7DC binds to PD-1(
 
 
 
/
 
 
 
)
cells and enhances T cell killing in a PD-1–independent mechanism. Our results demonstrate a
novel pathway for B7DC to promote tumor immunity and may reconcile the apparently
contradictory findings on the function of B7DC.
Key words: tumor immunity • costimulatory molecules • cytolytic T lymphocytes
 
Introduction
 
An important advance in the area of T cell costimulation is
the identification of several new functional members of the
B7 family, including B7H1/PDL1 (1, 2), B7H/B7RP (3,
4), B7H3 (5), and B7H2/B7DC/PDL2 (6). Although
B7H3 remains an orphan, B7RP/B7H is known to bind to
inducible costimulator (ICOS;
 
* 
 
3), whereas both B7H1
and B7DC were found to interact with PD-1 (2, 7), a pu-
tative negative regulator for immune function (8, 9). These
new members have cellular receptors distinct from those of
B7-1 and B7-2. In addition, the two known receptors,
ICOS and PD-1, are present on activated, but not resting,
T cells (10, 11).
Because of its broader tissue distributions, the new
members of the B7 family might be primarily involved in
the effector function of T cells after they migrate to the
tissues. For instance, the blockade of B7H–ICOS interac-
tion, even at a late stage of transplantation, was found to be
highly efficient in preventing allograft rejection (12). Corre-
spondingly, expression of B7H on the tumor cells promoted
cognate destruction of cancer cells in vivo, in addition to
enhanced clonal expansion and recall response (13, 14).
Targeted mutation of ICOS also resulted in reduced Th2-
mediated airway allergy and exacerbated experimental au-
toimmune encephalomyelitis (15–17).
Many have argued that negative regulation is critical for
homeostasis of the immune system. The fact that B7H1
and B7DC bind to PD-1, which was proposed as a nega-
tive regulator for immune receptors, raises an intriguing
possibility that these members may serve as a negative regu-
lator after activation of T cells. In support of this notion,
Freeman et al. (2) reported that both B7H1 and B7DC can
reduce T cell proliferation when coimmobilized into plas-
tic beads with anti-CD3 mAbs (7). This inhibitory activity
appears to depend on PD-1 as B7H1 and B7DC do not in-
hibit the PD-1(
 
 
 
/
 
 
 
) T cells (2, 7). Likewise, recent data
from Iwai et al. (18) suggest that PD-1–B7H1 interaction
may promote tumor escape. However, in earlier studies,
Dong et al. (1) found that recombinant B7H1 can costimu-
late cytokine production of T cells. Meanwhile, Tseng et
al. (6) observed a significant enhancing effect of B7DC on
T cell clonal expansion.
The disparate conclusions from different investigators re-
main to be reconciled. Recently, Dong et al. (19) reported
that B7H1 is expressed on a large array of cancer cells and
induces apoptosis of activated T cells. They also showed
that B7H1 induces activation-induced cell death. It is con-
ceivable that B7H1 and B7DC may have non–PD-1 recep-
tors that transduce a positive costimulatory signal. To assess
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Abbreviations used in this paper:
 
 CFSE, carboxyfluorescein succinimidyl
ester; CHO, Chinese hamster ovary; ICOS, inducible costimulator.T
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this possibility, we expressed B7DC on tumor cells and ana-
lyzed the role for B7DC in tumor growth and tumor-spe-
cific CTL response. Our results demonstrate that expression
of B7DC caused rapid rejection of tumors in syngeneic
mice and development of immunity to subsequent tumor
challenge, suggesting a positive role of B7DC in vivo. The
B7DC-mediated, enhanced immunity can be attributed to
both enhanced priming and effector function. More impor-
tantly, B7DC binds to PD-1(
 
 
 
/
 
 
 
) cells and enhances T
cell killing in a PD-1–independent mechanism. Our results
demonstrate a novel pathway for B7DC to promote tumor
immunity and may reconcile the apparently contradictory
findings on the function of B7DC and B7H1.
 
Materials and Methods
 
Construction of Expression Vectors.
 
To clone murine B7DC,
cDNA were prepared from dendritic cell culture. The B7DC was
amplified by RT-PCR using gctagcatgctgctcctgc as the forward
primer and gcggccgcctagatcctctttc as the reverse primer. The
PCR products were digested with NheI and NotI and cloned
into NheI and NotI sites of pcDNA3.1/Hygro
 
  
 
vector (Invitro-
gen). To produce B7DCIg, extracellular domain of B7DC were
amplified from B7DC cDNA using atgctgctcctgc as the forward
primer and acttacctgtccacgttctggg as the reverse primer. The PCR
product was cloned into the pIg vector (Novagen). B7DCIg fu-
sion gene was then inserted into the HindIII/KpnI site of
pcDNA3.1/Hygro
 
  
 
(Invitrogen). The construct was transfected
into Chinese hamster ovary (CHO) cells using the Fugene 6
transfection system (Boehringer). The hygromycin B–resistant
clones were expanded. The B7DCIg protein was purified using
protein G column. Murine PD-1 was amplified from cDNA pre-
pared from mouse spleen cells using aagcttatgtgggtccggc as the
forward primer and ggatcctcaaagaggcc as the reverse primer. The
PCR products were digested with HindIII and BamHI and
cloned into the HindIII and BamHI sites of pcDNA3.1/Hygro
 
 
 
and used to transfect CHO cells. The PD-1Ig was produced by
the same strategy as that used for the production of B7DCIg, with
the exception of the primers (forward, atgtgggtccggc; reverse, act-
tacctgtttgaaaccggcc) used. The primers for B7H1 are: forward, at-
gaggatatttgctggc; reverse, acttacctgtcctgttctgtgg.
 
Cell Lines and Experimental Animals.
 
Plasmocytoma J558 cells
were transfected with either vector alone (J558-Neo) or B7DC
(J558-B7DC) according to a previously described procedure (14).
Stable cell lines expressing B7DC were obtained after drug selec-
tion and were screened using the PD-1Ig.
Transgenic mice expressing TCR specific for tumor antigen
P1A35-43:L
 
d 
 
complex have been described (20). The TCR
transgenes were backcrossed with BALB/cByJ for at least eight
generations before they were used for this study. Wild-type
BALB/c mice were purchased from the National Cancer Insti-
tute. BALB/c mice with a targeted mutation of RAG-2 gene
were purchased from Taconic. PD-1(
 
 
 
/
 
 
 
)2C mice (21) were
provided by T. Honjo (Kyoto University, Kyoto, Japan) and
were bred into RAG-1(
 
 
 
/
 
 
 
) background at the University of
Chicago. The PD-1(
 
 
 
/
 
 
 
) RAG-1(
 
 
 
/
 
 
 
)2C mice have been
previously described (22). The bone marrows from both RAG-
1(
 
 
 
/
 
 
 
) PD-1(
 
 
 
/
 
 
 
) and RAG-1(
 
 
 
/
 
 
 
) PD-1(
 
 
 
/
 
 
 
)2C mice
were used to produce irradiation chimeras with syngeneic
C57BL/6j mice. 4–6 wk after reconstitution, the spleen cells
were harvested and stimulated with irradiated syngeneic BALB/c
 
spleen cells. Essentially all CD8 T cells were from 2C origin, as
confirmed by idiotype-specific antibody for the 2C TCR.
 
Antibodies.
 
PE-conjugated anti–PD-1, CyChrome-conju-
gated anti-CD8, PE-conjugated anti-V
 
 
 
8, and biotinylated anti–
H2-L
 
d 
 
mAbs were purchased from BD Biosciences. Anti-B7DC
mAb TY25 was purchased from eBioscience. Biotinylated clono-
typic antibodies against 2C was a gift from J. Chen (Massachusetts
Institute of Technology, Cambridge, MA).
 
Adoptive Transfer of Purified Transgenic T Cells.
 
Pools of spleen
and lymph node cells from the RAG-2(
 
 
 
/
 
 
 
) or RAG-2(
 
 
 
/
 
 
 
)
P1CTL transgenic mice were incubated with a cocktail of mAbs
(anti-CD4 mAb GK1.5, anti-FcR mAb 2.4G2, and anti-CD11c
mAb N418). After removal of unbound mAbs, the cells were in-
cubated with anti-Ig–coated magnetic beads. The antibody-
coated cells were removed by a magnet. The unbound cells con-
sisted of 
 
 
 
95% CD8 T cells with no detectable CD4 T cells. The
purified T cells were adoptively transferred into RAG-2(
 
 
 
/
 
 
 
)
mice that had large tumors. In some experiments, the CD8 T
cells were labeled with carboxyfluorescein succinimidyl ester
(CFSE). The labeled cells were either stimulated with tumor cells
in vitro or adoptively transferred into tumor-bearing hosts as pre-
viously described (23).
 
Tumorigenicity Assay.
 
5 
 
  
 
10
 
6 
 
J558 cells were injected into
the flanks as previously described (24). The tumor size and inci-
dence were determined by physical examination.
 
CTL Assays.
 
A 6-h 
 
51
 
Cr release assay was used to measure
CTL activity. The effector T cells were either P1CTL activated for
96 h with 0.1 
 
 
 
g/ml P1A peptide (20), or PD-1(
 
 
 
/
 
 
 
) and PD-
1(
 
 
 
/
 
 
 
)2C cells activated with spleen cells from BALB/c mice.
To determine the relative susceptibility of vector or B7DC-
transfected tumor cell lines, vector-transfected cells were labeled
with 0.5 ng/ml CFSE, whereas the B7DC transfectants were la-
beled with 5 ng/ml CFSE. The two cell types were mixed at an
 
 
 
1:1 ratio and incubated with effector T cells for 2 h. At the end
of the incubation, the cultures were fixed with 1% paraformalde-
hyde and analyzed by flow cytometry.
 
Flow Cytometry.
 
Cell surface expression of H-2L
 
d 
 
was de-
tected using biotinylated mAb 28-14-8 (BD Biosciences) fol-
lowed by PE-labeled streptavidin. To determine the binding of
H-2L
 
d
 
–peptide complex to transgenic T cells, we used the
H-2L
 
d
 
Ig dimer purchased from BD Biosciences according to the
manufacturer’s instructions. In brief, 3 
 
 
 
g peptides (P1A se-
quence, LPYLGWLVF; control peptide from murine cytomega-
lovirus, YPHFMPTNL) were incubated with 4 
 
 
 
g H-2L
 
d
 
Ig and
 
 
 
2 
 
microglobulin complex at 4
 
 
 
C for 48 h in a total volume of
200 
 
 
 
l. PE-conjugated monoclonal rat anti–mouse IgG1 anti-
bodies were added to the solution 1 h before it was used to stain
spleen cells from transgenic mice whose T cells had expressed the
TCR specific for the H-2L
 
d
 
–P1A peptide complex. After wash-
ing away the unbound complex, the spleen cells were fixed with
1% paraformaldehyde in PBS and analyzed by flow cytometry.
The binding of B7H1 and B7DC to T cells or PD-1 trans-
fected was determined by incubating 100 
 
 
 
g/ml biotinylated
IgG1 Fc, B7H1Ig, or B7DCIg with cells at 4
 
 
 
C for 30 min. After
washing away unbound fusion proteins, PE-conjugated streptavi-
din was added to measure the amount of fusion protein bound to
cells. In some experiments, CyChrome-conjugated anti-CD8
mAb was used together with the PE conjugate to mark CD8 T
cells. After three washes, the cells were fixed and analyzed by
flow cytometry.
In some experiments, 40-fold excess of unlabeled IgG1 Fc,
B7H1, or B7DC was incubated with PD-1(
 
 
 
/
 
 
 
)2C cells for 30
min before the addition of biotinylated fusion proteins. In yet an-T
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other setting, 800 
 
 
 
g/ml anti-B7DC mAb or control normal rat
IgG was incubated with 100 
 
 
 
g/ml of the biotinylated B7DC for
30 min before the mixtures were used to test their binding to
given cells.
 
Results
 
Expression of B7DC on Tumor Cells Results in Tumor
Rejection and Immunity to Parental Tumors.
 
To determine
whether B7DC has a positive or negative role in antitumor
immunity, we cloned B7DC by RT-PCR and transfected
it into the wild-type and MHC-deficient plasmocytoma
J558. As shown in Fig. 1 a, the vector and B7DC transfec-
tants are comparable in expression of H-2L
 
d 
 
but differing in
B7DC expression, as revealed by their binding to PD-1Ig.
To test the effect of B7DC on tumorigenicity of the
J558 tumor cells, we injected the J558 cells that had been
transfected with either vector alone or B7DC into synge-
neic BALB/c mice. As shown in Fig. 1 b, most mice that
were injected with vector-transfected J558 cells (J558-Neo)
developed tumors that grew progressively. In contrast, the
mice that received B7DC-transfected J558 cells (J558-
B7DC) had initial tumor growth followed by complete
remission. To determine if the difference in the growth
kinetics was due to the intrinsic tumorigenicity of the J558-
Neo and J558-B7DC, we injected the same dose of J558-
Neo and J558-B7DC cells into the syngeneic RAG-2(
 
 
 
/
 
 
 
)
mice, which are devoid of T and B cells. As shown in
Fig. 1 c, the two cell lines grew at the same rate in the
RAG-2(
 
 
 
/
 
 
 
) mice. Thus, the preferential rejection of the
J558-B7DC must be mediated by T or B lymphocytes. We
then depleted either CD4 or CD8 T cells by treatment
with depleting monoclonal antibodies. As shown in Fig. 1
d, the tumor rejection was mediated by CD8 T cells as the
immunity can be abrogated by anti-CD8, but not anti-
CD4, mAbs (Fig. 1 e).
2 mo after the rejection of B7DC-transfected tumors, we
rechallenged the tumor-free mice with the untransfected
J558 cells. Although all naive mice develop J558 tumors
within 7 d, none of the mice that had rejected the J558-
B7DC tumors developed tumors (Fig. 1 e). Continuous
observation over a 4-mo period revealed no tumors in the
primed mice. Thus, J558-B7DC induced long-lasting im-
munity to J558 tumor cells in immune-competent hosts.
It has been established that a major tumor antigen in the
J588 tumor cells is P1A peptide AA35-43 presented by
H-2L
 
d 
 
(25). Therefore, we analyzed the number of P1A-
reactive T cells in mice challenged with either J558-Neo or
J558-B7DC, using H-2L
 
d 
 
dimer loaded with either the
P1A peptide or a control H-2L
 
d
 
–binding peptide. As
shown in Fig. 2, P1A-reactive T cells were barely detect-
able in mice challenged with the J558-Neo tumor cells. In
contrast, the mice that received the J558-B7DC produced
high numbers of P1A-reactive CD8 T cells. On average,
Figure 1. B7DC induced rapid rejection
of CD8 T cell–dependent rejection of J558
tumor cells. (a) Expression of H-2Ld  and
B7DC on J558 tumor variants. Parental J558
cells and its H-2–deficient variants were
transfected with either vector alone (I, III) or
B7DC (II, IV). The cell lines were stained
with either biotinylated anti–H-2Ld  mAb
(red lines) or PD-1Ig fusion protein (blue
lines), followed by PE-conjugated second
step reagents. (b) Rapid rejection of J558-
B7DC, but not the J558-Neo, tumors by
BALB/c mice. 5   106 tumor cells were in-
jected into the flank and the tumor inci-
dence (top) and growth kinetics (bottom)
were monitored by physical examination.
Data shown are representative of two inde-
pendent experiments with two different
clones of J558-B7DC. Each experiment
consisted of 10 mice per group. (c) Compa-
rable tumorigenicity of J558-Neo and J558-
B7DC in RAG-2( / ) BALB/c mice. As
in b, except that RAG-2( / ) BALB/c
mice were used as hosts. Data shown are
growth kinetics and are representative of two
independent experiments with five mice per
group. (d) CD8 T cells are necessary for re-
jection of J558-B7DC. BALB/c mice were
depleted of either CD4, CD8 T cells, or
both, with monoclonal antibodies on days
 2, 0, and  2 of injection with 5   106
J558-B7DC tumor cells. (e) Long-lasting
immunity to parental J558 tumor cells in
mice that have rejected the J558-B7DC.
Naive or J558-B7DC–primed BALB/c mice (n   5) were challenged with 5   106 J558 tumor cells in the flank and the growth kinetics of tumors in naive
mice were monitored. All naive mice developed tumors within 1 wk, whereas no primed mice developed tumors over the 4-mo period observed.T
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1% of CD8 T cells in the spleen of the J558-B7DC–
primed mice were specific for the P1A peptide, whereas
the numbers of antigen-specific T cells were 
 
 
 
10-fold
lower in the mice that were challenged with the J558-Neo
tumor cells. Thus, B7DC may deliver a positive signal to
enhance immunity in vivo.
We had isolated MHC-deficient variants of the J558 tu-
mor cells that lacked multiple antigen-presentation genes,
including LMP-2, LMP-7, TAP-1, and TAP-2 (26). Our
previous studies revealed that the MHC-deficient tumor
cells are capable of cross-, but not direct, priming of P1A-
specific T cells (27). To test if expression of B7DC on the
tumor cells could enhance cross-priming, we transfected
the B7DC into an MHC-deficient variant of J558 (Fig. 1
a). As shown in Fig. 2 a, expression of B7DC on the
MHC-deficient cell line was insufficient to induce signifi-
cant priming of P1A-reactive T cells. Because the nominal
antigen P1A gene is expressed on both parental and MHC-
deficient J558 cells (Fig. 2 b), the enhanced priming in-
duced by B7DC is most likely due to its effect in enhancing
direct stimulation of T cells by the B7DC
 
  
 
tumor cells.
 
B7DC Promotes Clonal Expansion of Tumor-specific CTL.
 
To determine if B7DC can promote clonal expansion
of the P1A-reactive T cells, we injected CFSE-labeled
P1CTL into either naive mice or those that had received
either J558-Neo or J558-B7DC and analyzed the rate of T
cell division in vivo. As shown in Fig. 3, a–d, in the ab-
sence of tumor cells, the P1CTL underwent little, if any,
homeostatic proliferation during the 3-d period studied.
Although no division of T cells could be observed on day
1, significant expansion of T cells was found in mice bear-
ing the J558 tumors by days 2 and 3. In mice bearing the
J558-Neo tumors, most cells were at divisions 1–4, with a
few cells at division 5. In mice bearing J558-B7DC, the
majority of the cells were at divisions 4–5. Although the
difference is less marked on day 3, there were substantially
more cells at division 9 in mice bearing the J558-B7DC
tumors than in those that bore the J558-Neo tumors. The
accelerated division resulted in increased number of anti-
gen-specific T cells in the spleen of the J558-B7DC tumor-
bearing mice. Thus, the activated T cells were not immedi-
ately eliminated, which contrasted to what was reported for
B7H1-expressing tumors (19).
To determine the long-term consequence of the B7DC
costimulation, we adoptively transferred purified P1CTL
into mice with tumors of 
 
 
 
1.5 cm in diameter. 1 mo after
the adoptive transfer, the amounts of P1CTL in the PBL
were monitored by flow cytometry. Consistent with the
increased clonal expansion during the induction phase,
mice that bore B7DC-transfected tumors had substantially
higher numbers of tumor-specific transgenic T cells at 1
mo after adoptive transfer (Fig. 3, e–g). On average, 
 
 
 
60%
of the peripheral blood lymphocytes in the J558-B7DC tu-
mor-bearing mice were the adoptively transferred trans-
genic T cells, whereas 
 
 
 
10% of the PBL in the J558-Neo
tumor-bearing mice were transgenic T cells. Taken to-
gether, the data in Figs. 2 and 3 demonstrate that expres-
sion of B7DC on the tumor cells enhanced, rather than
suppressed, tumor-specific T cell response.
 
B7DC Enhances Rejection of Large, Established Tumors by
Promoting Effector Function of T Cells.
 
In addition to its
role in promoting the priming of tumor-reactive T cells,
the B7DC may also promote effector function of CTL. We
performed two types of experiments to evaluate this possi-
bility. As shown in Fig. 4 a, in a conventional CTL assay
using activated P1CTL as the effector, we found that the
Figure 2. B7DC promotes di-
rect, but not cross-, priming of
P1A-specific T cells. (a) P1A–
H-2Ld–reactive CD8 T cells in
the spleen of mice that were im-
munized with 5   106 of one of
the four J558 variants. Spleen
cells were harvested 4 wk after
tumor cell challenge and stained
with FITC-labeled anti-CD8
mAb and H-2LdIg loaded with
either a control peptide or the
P1A peptide. Data shown are
gated CD8 T cells with the per-
cent of dimer-binding cells indi-
cated in each panel. (b) Sum-
mary of percent of P1A-specific
cells among the CD8 T cells.
The data shown were the per-
centages of H-2LdIg–P1A–bind-
ing cells after subtracting those of
H-2Ld–ctrl peptide binding cells.
(c) Expression of tumor antigen
P1A among all J558 variants as
analyzed by RT-PCR. GAPDH
products were used as control for
cDNA quality.T
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J558-Neo was much less efficiently lysed by P1CTL. To
confirm this, we labeled the J558-Neo and J558-B7DC
with different concentrations of CFSE to make them dis-
tinguishable by flow cytometry and mixed them at an  1:1
ratio. The P1CTL were added and incubated for 2 h. The
cell mixture was then analyzed by flow cytometry to deter-
mine the relative amounts of J558-Neo and J558-B7DC
cells. As shown in Fig. 4, b and c, P1CTL preferentially re-
moved the J558-B7DC as the ratio of J558-Neo over J558-
B7DC increased in a dose-dependent manner. Thus, al-
though tumor cells can be killed by CTL even in the
absence of B7DC, the latter substantially increased target
susceptibility of the tumor cells.
To test if the expression of B7DC on tumor cells in-
creased their susceptibility to CTL therapy in vivo, we
compared the J558-Neo and J558-B7DC tumors for their
Figure 3. B7DC promotes clonal expansion of P1A-specific transgenic T cells in tumor-bearing mice. (a–d) The effect of B7DC on clonal expansion
of the transgenic T cells. CFSE-labeled transgenic CD8 T cells were inoculated in either tumor-free mice (green lines), those that bore J558-Neo (red
lines), or J558-B7DC (blue line) tumors. Spleen cells were harvested on days 1 (a), 2 (b), and 3 (c) after inoculation into mice with a comparable tumor
size. The percentages of T cells accumulated in the first 3 d are summarized in d. (e–g) The number of transgenic T cells 4 wk after adoptive therapy of
large tumor cells. The PBL were analyzed for the presence of transgenic T cells using mAbs to identify the CD8  V 8  T cells. e and f depict represen-
tative profiles of PBL from mice that bore either the J558-Neo (e) or J558-B7DC (f) tumors. The percent of gated double CD8  V 8  positive T cells in
each mouse (n   5 per group) are summarized in g. See Fig. 5 for the therapeutic effect of transgenic T cells.
Figure 4. Preferential lysis of
J558-B7DC by activated P1CTL
as determined by 51Cr release (a)
and competitive lysis assay (b and
c). The representative FACS®
profiles of cell mixture in the ab-
sence (top) or presence of
P1CTL (bottom). Only gated
CFSE  cells with viable cellular
scatters were presented. Data are
representative of three indepen-
dent experiments. (c) Ratios of
J558-Neo/J558-B7DC as a func-
tion of E/T, calculated based on
the percentage of the CFSElow
versus that of the CFSEhigh cells.
The number of target cells used
for E/T calculation is the sum
of two types of tumor cells in
the cultures.T
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response to therapy with P1CTL. As shown in Fig. 5, the
P1CTL were injected when the tumors were  1.5 cm in
diameter. In the J558-Neo tumor group, one tumor-bear-
ing mouse died within 1 wk of CTL therapy with no sign
of tumor regression, whereas the other four initially had
different degrees of regression. However, rapid recurrence
was observed in all mice. The recurrent tumors grew pro-
gressively, and by 7 wk of CTL therapy, euthanasia became
necessary. In contrast, regression was found in all J558-
B7DC tumors. With somewhat different kinetics, three
mice rejected the large tumors completely and survived for
 200 d. Two mice had recurrent tumors and were killed 2
mo after treatment. The fact that the majority of mice with
large J558-B7DC tumors achieved long-term survival
demonstrates the important role of B7DC in promoting
CTL effector function in vivo.
PD-1 Is Not Required for the B7DC-enhanced Induction and
Effector Function of CTL: Evidence for a Non–PD-1 Receptor
for B7DC. A previous study revealed that B7DC–PD-1
interaction down-regulated T cell activation (7), whereas
our data presented here and the original work of Tseng et
al. (6) suggest that B7DC may promote T cell function.
One hypothesis that may reconcile these observations is
that there might be non–PD-1 receptors that mediate the
costimulation by B7DC. To test this hypothesis, we set to
determine whether B7DC could bind to PD-1( / ) T
cells and if so, whether this interaction can promote the
CTL effector function. We produced a fusion protein
comprised of the extracellular domain of B7DC and the Fc
portion of human IgG1. We then compared B7DCIg
binding to PD-1( / ) and PD-1( / )2C cells by flow
cytometry. As shown in Fig. 6 a, both PD-1( / ) and
PD-1( / )2C cells bound strongly to B7DCIg, but not
to the control IgG Fc. These results demonstrated that
B7DC also has a non–PD-1 receptor on activated T cells.
To determine whether PD-1 and non–PD-1 receptor
binds to the same region on B7DC, we tested the effect of
a commercially available anti-B7DC antibody (TY25) for
its ability to block B7DC binding to PD-1 and the non–
PD-1 receptor. Anti-B7DC mAb or control rat IgG were
incubated with biotinylated B7DCIg. The mixtures were
then tested for B7DC binding to either PD-1–transfected
CHO cells or PD-1( / )2C cells. As controls, biotiny-
lated Fc fragment or B7DC was used without previous in-
cubation. As shown in Fig. 6 b, biotinylated B7DC, but
not the Fc fragment, binds the PD-1–transfected cells. This
binding is substantially reduced by preincubation with anti-
B7DC mAb, but not with control normal rat Ig. Thus, the
anti-B7DC antibodies can block B7DC–PD-1 interaction.
Surprisingly, the anti-B7DC antibody significantly en-
hanced binding of B7DC to PD-1( / ) cells. Thus,
B7DC must have used a different epitope to interact with
the non–PD-1 receptor on the PD-1( / )2C cells. The
enhanced binding is likely due to the multimerization of
the B7DCIg by the nonblocking anti-B7DC mAb.
Because B7H1 also appears to have a non–PD-1 receptor
(19), we performed a cross-blocking experiment to deter-
mine whether B7DC and B7H1 bound to the same non–
PD-1 receptor. As shown in Fig. 6 c, PD-1( / )2C cells
bound to B7H1, but not to control IgG1 Fc. The nature of
B7H1 binding is less clear as 40-fold excess of unlabeled
B7H1 failed to block its binding. B7DCIg bound signifi-
cantly better than B7H1Ig. This binding can be substantially
blocked by B7DCIg, but not by either B7H1Ig nor control
IgG1 Fc. The differential PD-1–independent binding and
lack of cross-blocking between B7H1 and B7DC demon-
strate that the non–PD-1 receptor for B7DC is distinct from
the putative non–PD-1 receptor for B7H1.
To determine whether the putative non–PD-1 receptor
can promote the induction of CD8 T cells, we stimulated
CFSE-labeled PD-1( / )2C T cells with the J558-Neo
and J558-B7DC in vitro. At 48, 72, and 96 h after culture,
the distribution of CFSE intensity among the transgenic T
cells was determined by flow cytometry. The two cell
lines expressed the same levels of H-2Ld (Fig. 7 a), yet the
B7DC transfectants induced substantially faster division of
the T cells (Fig. 7 b). At 48 h, more T cells in the J558-
B7DC–stimulated group were undergoing division. At 72 h,
most of the T cells in the J558-Neo–stimulated group di-
vided less than three times, but the majority of those in the
J558-B7DC–stimulated group divided four or five times.
Perhaps due to CFSE over-dilution, the differences were
less remarkable at 96 h. These results demonstrate that
B7DC can promote T cell proliferation by a PD-1–inde-
pendent mechanism.
Again, we used two assays to test whether the B7DC en-
hanced the effector function of 2C transgenic T cells that
Figure 5. Transgenic T cell therapy of large J558-Neo and J558-B7DC
tumors. 5   106 P1CTL were purified from the TCR transgenic mice
and injected intravenously into mice with large tumor burden. The
growth kinetics of tumors was measured using a caliber. The points of
mouse death are indicated with a cross. Note that at 4 wk after T cell
therapy, the cells in the PBL were analyzed and the data are presented in
Fig. 3, e–g.T
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recognize the H-2Ld on the J558 tumor cells. Using the ap-
proach illustrated in Fig. 4, we compared the ratio of J558-
B7DC and J558-Neo after a 2-h coincubation with PD-
1( / ) and PD-1( / )2C cells. Both PD-1( / ) and
PD-1( / )2C preferentially eliminated J558-B7DC cells,
as the ratio of J558-Neo/J558-B7DC increased in the pres-
ence of CTL (Fig. 8 a). When varying numbers of effector
were used, we observed greater preference of B7DC lysis
with increasing dosage of CTL (Fig. 8 b). Surprisingly, PD-
1( / )2C showed a much stronger preference for the
J558-B7DC cells. These results demonstrate that PD-1 is
not required for the enhanced cytolysis of J558-B7DC.
In the conventional CTL assay, both PD-1( / ) and
PD-1( / )2C cells preferentially killed the J558-B7DC
over the J558-Neo cells (Fig. 8 c). In multiple experiments,
we consistently observed stronger cytolytic activity in PD-
1( / )2C cells, which is consistent with a previous report
(21). Moreover, the difference between J558-Neo and
J558-B7DC was not caused by clonal variation in suscepti-
bility to 2C cells, as demonstrated by CTL assays involving
two independent clones in each group (Fig. 8 d). Taken to-
gether, the data presented in Fig. 7 demonstrate that B7DC
cells enhance CTL killing via a non–PD-1 receptor.
Discussion
The recent identification of several new members of the
B7 family of costimulatory molecules raises an interesting
issue on the function of these molecules. The function of
B7H1 and B7DC, which interact with PD-1, remains con-
troversial. Dong et al. (1) and Tseng et al. (6) reported that
B7H1 and B7DC promoted T cell proliferation. Recently,
Dong et al. (19) reported that B7H1 is widely expressed on
multiple lineages of cancer cells and can promote pro-
grammed cell death of cancer-specific T cells in both PD-
1–dependent and PD-1–independent mechanisms. Tumor
expression of B7H1 may allow its evasion of T cell immu-
nity. On the other hand, Freeman et al. (2) have reported
that both B7H1 and B7DC can inhibit T cell proliferation
by PD-1–dependent mechanisms (7). Here we investigated
the function of B7DC in an antitumor CTL response in
vivo. Our results revealed that B7DC promotes tumor re-
jection by T cells via a PD-1–independent mechanism.
Distinct Function of B7DC and B7H1 in Inducing Antitumor
Immunity. B7H1 and B7DC share a common receptor,
PD-1, and were reported to induce PD-1–dependent in-
hibition of T cell proliferation (2, 7). However, these two
molecules have significant differences in tissue distribu-
tions (6, 28). Stimulation of T cells in the presence of
B7H1 led to a significant increase in IL-10 production (1).
In contrast, coligation with TCR ligand and B7DC pro-
moted Th1-type cytokine production (6). With regard to
tumor immunity, B7H1 induces apoptosis of antigen-
reactive T cells and inhibits immunity induced by B7-1
(19). Recent data also suggest that B7H1–PD-1 interac-
tion assists tumor evasion of host immunity. The function
of B7DC in tumor immunity has not been reported. Here
we presented several lines of evidence that support the
conclusion that unlike B7H1, B7DC promotes, rather
than inhibits, antitumor immunity.
Figure 6. Characterization of the non–PD-1 recep-
tors for B7H1 and B7DC. (a) Activated CTL express a
PD-1–independent receptor for B7DC. Spleen cells
from chimera mice with bone marrow from either
PD-1( / )2C or PD-1( / )2C were activated with
BALB/c mice for one or two rounds. Activated T cells
were harvested and their expression of the 2C receptors
on all CD8 T cells was confirmed by flow cytometry.
Expression of PD-1 and B7DC receptors were deter-
mined using either 10  g/ml PE-conjugated anti–PD-1
mAb, 100  g/ml biotinylated B7DCIg, or 100  g/ml
human IgG1 Fc as control. CD8 T cells were marked
with CyChrome-conjugated anti-CD8 mAb. Data
shown are profiles of gated CD8 T cells and are repre-
sentative of at least five independent experiments. (b)
B7DC binds PD-1 and the putative non–PD-1 receptor
via distinct epitopes. PD-1–transfected CHO cells (top)
and PD-1( / )2C cells (bottom) were stained with
biotinylated B7DC or IgG1 Fc as control. The block-
ers, 800  g/ml anti-B7DC or control Rat Ig, were in-
cubated with B7DC before the addition of CHO or T
cells. The distinct effect of anti-B7DC on PD-1–B7DC
binding has been repeated three times. (c) Lack of cross-
blocking between B7DC and B7H1. As in b, except
that the blockers were 40-fold excess of IgG1 Fc,
B7H1Ig, or B7DCIg. The blockers were added to cells
30 min before the addition of biotinylated reagents.
The PD-1( / )2C cells used in b and c had been
stimulated three to five times with irradiated BALB/c
cells in the presence of IL-2 and IL-7, and were com-
prised exclusively of 2C  CD8 T cells. Data shown are
representative of at least three independent experiments.T
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First, B7DC-transfected tumor cells are rapidly rejected
by immune-competent hosts, and the mice that rejected
B7DC-transfected tumor cells developed immunity against
a subsequent challenge with unmodified parental tumors.
This is distinct from B7H1-transfected tumor cells, which
were not rejected (19).
Figure 7. B7DC promotes clonal expansion of PD-
1( / )2C cells. (a) Characterization of H-2Ld and B7DC
expression on the stimulatory cells by flow cytometry.
Data shown are histograms depicting expression of H-2Ld
(red lines) and B7DC (blue lines) of the J558-Neo (top)
and J558-B7DC clones (bottom). (b) Analysis of T cell di-
vision. J558-Neo and J558-B7DC cells (2   105/well of
the 6-well tissue culture plate) were irradiated for 10,000
rads and used as stimulators for 4   106/well CFSE-labeled
spleen cells isolated from chimera mice constituted with
bone marrow from PD-1( / ) RAG-1( / )2C mice.
At 48, 72, and 96 h after stimulation, the viable cells were
stained with the 2C TCR-specific mAb and analyzed by
flow cytometry for distribution of CFSE intensity. The
data shown are the histograms depicting the distribution of
CFSE intensity of the gated 2C cells. The B7DC-enhanced
proliferation has been repeated twice.
Figure 8. Preferential lysis of J558-B7DC over
J558-Neo by a PD-1–independent mechanism. Acti-
vated PD-1( / ) and PD-1( / )2C cells were used
as effector cells, whereas labeled J558-B7DC and J558-
Neo were used as targets. (a) When J558-B7DC and
J558-Neo were cocultured with CTL, J558-B7DC
cells were preferentially eliminated. E/T   10. Data
shown are representative of three independent experi-
ments, which have been repeated with two indepen-
dent clones from each group. (b) Ratios of J558-Neo/
J558-B7DC at different E/T. (c) Cytolysis of J558-
Neo and J558-B7DC as measured by conventional
51Cr release assay. Data shown are representative of
three independent experiments. (d) Cytolysis of two
independent J558-Neo and J558-B7DC clones by
PD-1( / )2C. Data are representative of two inde-
pendent experiments.T
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Second, unlike B7H1-expressing tumor cells, which re-
duce the number of antigen-specific T cells in vivo (19),
B7DC-transfected tumor cells substantially increased the
number of antigen-specific T cells. This has been demon-
strated with both transgenic and nontransgenic T cells. In
both models, the P1A-specific CTL divided more rapidly
and accumulated at higher numbers in response to the J558-
B7DC tumors. Using H-2–deficient tumor cells that medi-
ate cross-, but not direct, priming, we were unable to dem-
onstrate any effect of B7DC on cross-priming. Therefore, it
is likely that the main function of B7DC in T cell priming is
to enhance direct activation of T cells by the tumor cells.
Although both B7H1 and B7DC bind to PD-1( / ) T
cells, we observed two significant differences in their bind-
ing to T cells. First, because B7H1 binding to the PD-1( / )
cells cannot be blocked by 40-fold excess of unlabeled
B7H1, the significance of the non–PD-1 receptor for B7H1
in the 2C cells is less certain. In contrast, the B7DC binding
to PD-1( / ) T cells is considerably stronger and can be
blocked by unlabeled B7DC. Second, we have failed to de-
tect cross-blocking between the two molecules in their
binding to PD-1( / ) cells, even though both molecules
have strong saturable binding to PD-1–transfected CHO
cells (unpublished data). These two findings suggest that the
non–PD-1 receptor for B7DC may not be shared with
B7H1. The distinct non–PD-1 receptors for B7H1 and
B7DC may help to explain their distinct biological function.
B7DC Enhances the Effector Function of Cancer-specific T
Cells. Several lines of evidence point to an important
function of B7DC in promoting cytolysis of tumor cells by
CTL. First, B7DC-transfected target cells are preferentially
lysed by CTL specific for either P1A–H-2Ld complex or al-
logeneic H-2Ld. Second, when B7DC-transfected and
mock-transfected tumor cells are cocultured with CTL, the
B7DC-transfected tumor cells are preferentially eliminated.
Third, B7DC transfection conveys high susceptibility of
large tumors to therapy by tumor-specific T cells in vivo.
Thus, B7DC joins B7H and B7-1 in promoting the effec-
tor function of CTL (14, 20, 24, 29) while differing from
B7H1, which reduces the efficiency of cancer immunity by
inducing apoptosis of CTL (19). Because many cancer pa-
tients already have expanded cancer-specific CTL, which
can coexist with antigen-bearing cancer cells (30, 31), a
critical aspect of cancer immunotherapy is to increase the
effector function of cancer-specific T cells. Expression of
costimulatory molecules, such as B7–1, B7H, and B7DC,
may offer a valuable approach.
B7DC Promotes T Cell Induction and Effector Function by
PD-1–independent Mechanisms. Our results documented
here differ significantly from both what was described for
its PD-1–dependent function and what was described for
B7H1 in the tumor model. To address the potential contri-
bution of PD-1 in tumor rejection, we compared the effec-
tor function of PD-1( / ) and PD-1( / )2C cells. Our
results demonstrated that both PD-1( / ) and PD-1( / )
2C cells preferentially lysed B7DC-transfected tumor
cells. Thus, PD-1 is not required for the B7DC-mediated
enhancement of T cell effector function. Similarly, the
B7DC-transfected tumor cells are more potent stimulators
for the PD-1(   ) T cells. In fact, we have consistently
observed that PD-1( / )2C cells are more responsive to
B7DC-mediated costimulation for effector function. Al-
though this would argue for the notion that PD-1 may me-
diate a negative regulation through B7DC, it is also possi-
ble that PD-1–deficient T cells and their wild-type
counterpart are programmed differently due to a significant
function of PD-1 in T cell development (32).
The existence of a PD-1–independent receptor for
B7DC is also confirmed by significant binding of PD-1( / )
2C cells by B7DC. Interestingly, an anti-B7DC antibody
that blocks B7DC–PD-1 interaction enhanced the binding
between B7DC and PD-1( / ) T cells. Because the 2C
cells used in this study did not express B7DC, the enhanced
binding must be due to anti-B7DC–B7DC interaction,
which likely produces higher valancy of B7DC. The oppo-
site effect of the mAb demonstrates that B7DC uses distinct
epitope to bind PD-1 and the putative non–PD-1 receptor.
This differs from B7-1/B7-2–CD28/CTLA4 interaction,
which we and others have demonstrated to use an overlap-
ping site (33, 34).
In conclusion, we have revealed a costimulatory function
of B7DC in antitumor immunity. This is achieved by both
enhanced T cell priming and effector function. Our studies
demonstrate the existence of a non–PD-1 costimulatory re-
ceptor(s) for B7DC, which is responsible for the enhanced
effector function for B7DC-expressing tumor cells. The in-
volvement of the novel pathway may help to reconcile the
conflicting findings on the function of B7DC.
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